# PsyMed Ventures

> PsyMed Ventures is a VC fund backing Health Care and Biotechnology. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 25
- Last investment: Oct 2025
- Lead investor: 0%
- Fund size: $25M
- Last fund: Jan 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/psymed-ventures
- X (Twitter): https://twitter.com/PsymedVentures
- Website: https://psymed.ventures/

Psymed Ventures is an investment syndicate that invests in early-stage psychedelics companies. The firm was founded in 2020 by Matias Serebrinsky and Dina Burkitbayeva and is headquartered in San Francisco, California, United States.

## Contacts

5 contacts available for PsyMed Ventures. Shizune tracks 5 team members at PsyMed Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/psychedelic-medicine-syndicate?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $680k–$21M |
| Pre-Seed | $3.5M–$8M |
| Series A | $4.8M–$70M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 52% |
| Biotechnology | 11 | 44% |
| Medical | 7 | 28% |
| Therapeutics | 4 | 16% |
| Neuroscience | 3 | 12% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 36% |
| Series A | 8 | 32% |
| Pre-Seed | 2 | 8% |
| Venture - Series Unknown | 2 | 8% |
| Series B | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 60% |
| Canada | 1 | 4% |
| Israel | 1 | 4% |
| Ireland | 1 | 4% |
| Australia | 1 | 4% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Caitlin Ner | Chief of Staff; Chief of Staff | 0 | https://shizune.co/investors/profile/caitlin-ner-63ce |
| Dina Burkitbayeva | Founder | 2 | https://shizune.co/investors/profile/dina-burkitbayeva |
| Garri Zmudze | Venture Partner | 8 | https://shizune.co/investors/profile/garri-zmudze |
| Greg Kubin | Founder | 0 | https://shizune.co/investors/profile/greg-kubin |
| Matias Serebrinsky | Co-founder and General Partner | 0 | https://shizune.co/investors/profile/matias-serebrinsky |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aerska | Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $21M | Seed | Oct 01, 2025 |  |
| Sanmai | Sanmai is a neurotechnology company developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders |  |  | Jun 23, 2025 |  |
| Sanmai | Sanmai is a neurotechnology company developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders | $12M | Series A | Jun 23, 2025 |  |
| Jimini Health | Jimini’s mission is to radically improve the efficacy of mental health care across the world. Jimini has developed a novel care model that combines teletherapy sessions with personalized AI support. With Jimini, your therapy care team includes your licensed clinician and Sage, your always-available AI therapy assistant, who work together to helpyou achieve your goals.Founded in 2023 by a team of seasoned AI and biotech entrepreneurs, health tech veterans, and psychology researchers, Jimini puts science and tech first, using safe, purpose-built patient-facing technology that works exclusively under clinical oversight and high safety standards.World leaders in psychology designed Jimini’s care model to ensure that every part of the patient's journey is clinically beneficial. Jimini does not believe that LLMs should replace clinicians; rather, AI will help therapists deliver higher-quality care and focus on the most complex parts of their job. Jimini’s care model is first and foremost led by excellent clinicians.Jimini is committed to improving mental health quality and creating radically better, more modern, and clinically efficacious mental health experiences for patients. | $8M | Pre-Seed | Nov 19, 2024 |  |
| Neurode | Neurode is developing a non-invasive wearable device to improve cognitive performance for people with neurological conditions like ADHD. The headset aims to treat and monitor the symptoms of ADHD as well as a paired app that tracks your improvements and shares them with your clinician. | $3.5M | Pre-Seed | Sep 13, 2024 |  |
| Ancilia Biosciences | Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. | $4.2M | Venture - Series Unknown | Jul 17, 2024 |  |
| Remepy | Remepy is biotechnology research pioneering hybrid drugs. The company believes that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms ofAction™.It was founded in 2022 and is located in Ramat Gan, Tel Aviv. | $10M | Seed | May 01, 2024 |  |
| Motif Neurotech | Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $18.8M | Series A | Jan 24, 2024 |  |
| Motif Neurotech | Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $2M | Seed | Feb 28, 2023 |  |
| Journey Clinical | Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care. | $8.5M | Series A | Jan 24, 2023 |  |

10 of 25 investments shown.

## Co-investors
- [Noetic Fund](https://shizune.co/investors/profile/noetic-fund) — VC Fund, 5 deals together
- [Empath Ventures](https://shizune.co/investors/profile/empath-ventures) — VC Fund, 4 deals together
- [Lionheart Ventures](https://shizune.co/investors/profile/lionheart-ventures) — VC Fund, 4 deals together
- [Negev Capital](https://shizune.co/investors/profile/negev-capital) — VC Fund, 4 deals together
- [Palo Santo Fund](https://shizune.co/investors/profile/palo-santo-venture-fund) — VC Fund, 4 deals together
- [Mystic Ventures](https://shizune.co/investors/profile/mystic-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Medical Investors in Australia](https://shizune.co/investors/medical-investors-australia)
- [Medical Device VC Funds in Australia](https://shizune.co/investors/medical-device-vc-funds-australia)
- [Medical Device VC Funds in Oceania](https://shizune.co/investors/medical-device-vc-funds-oceania)
- [Biotechnology VC Funds in Ireland](https://shizune.co/investors/biotechnology-vc-funds-ireland)
- [Biotech Investors in Ireland](https://shizune.co/investors/biotech-investors-ireland)
- [Biotech VC Funds in Ireland](https://shizune.co/investors/biotech-vc-funds-ireland)

## FAQ

### What does PsyMed Ventures invest in?

PsyMed Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is PsyMed Ventures's check size?

PsyMed Ventures typically joins rounds of $680k–$21M at Seed, $3.5M–$8M at Pre-Seed and $4.8M–$70M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds PsyMed Ventures participates in.

### How do I contact PsyMed Ventures?

Public channels for PsyMed Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at PsyMed Ventures?

The team at PsyMed Ventures includes Caitlin Ner (Chief of Staff; Chief of Staff), Dina Burkitbayeva (Founder) and Garri Zmudze (Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co